Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer.
Saved in:
| Title: | Efficacy and Safety Results From a Phase 2, Placebo-Controlled Study of Onartuzumab Plus First-Line Platinum-Doublet Chemotherapy in Advanced Squamous-Cell Non-Small Cell Lung Cancer (sq NSCLC): Metastatic Non-Small Cell Lung Cancer. |
|---|---|
| Authors: | Hirsch, F.R.1, Govindan, R.2, Zvirbule, Z.3, Braiteh, F.4, Rittmeyer, A.5, Belda Iniesta, C.6, Isla, D.7, Cosgriff, T.8, Boyer, M.9, Ueda, M.10, Phan, S.10, Gandara, D.11 |
| Source: | International Journal of Radiation Oncology, Biology, Physics. Nov2014 Supplement, Vol. 90 Issue 5, pS37-S37. 1p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
